CLINICAL_TRIALS trial_result · 2024-08-13

Clinical Trial Update: A Phase 3, Open-Label Extension of COURAGE-ALS (CY 5031) [Phase 3]

Phase 3 open-label extension of COURAGE-ALS investigating CY 5031 was terminated; results were posted in August 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Sponsor: Cytokinetics | Conditions: Amyotrophic Lateral Sclerosis | Phase 3 | Status: TERMINATED | Results posted: 2024-08-13